Skip to content

Trial · Interventional

CompletedPhase 4Registry data

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes

NCTNCT03297879 (opens ClinicalTrials.gov in a new tab)Other id2015-科 144
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 4
Enrollment
230 participants (actual)
Sponsor
Beijing Chao Yang Hospital · Other
Design
Not randomized · Open label (no masking)
Countries
Not stated
Start
1 Jan 2013
Primary completion
28 Feb 2016
Completion
28 Feb 2016
First posted
29 Sept 2017
Last update posted
2 Oct 2017
Conditions
Type2 Diabetes

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20132014201520162017
  1. Ph 4

    Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes

    NCT03297879

    1 Jan 2013 to 28 Feb 2016

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The present study assessed the therapeutic effect of exenatide and metformin as the initial therapy in overweight/obese patients with newly diagnosed Type 2 diabetes (T2D).

Interventions

  • Exenatide or metformin hydrochlorideDrug

Arms2

  • Experimental

    exenatide group

    The drug-naïve, overweight or obese patients with newly diagnosed T2D

  • Active comparator

    metformin group

    The drug-naïve, overweight or obese patients with newly diagnosed T2D

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. The change of HbA1c

    Time frame · baseline and 12 weeks

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

1 study on this page

PubMed tag: none · 2022

6 results

The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 Diabetes.

Zhang et al. 2022Frontiers in endocrinologycited by 21

PMID 35432194PMC9009038DOI 10.3389/fendo.2022.677202PUB-35432194

CC BY6 results
Download PDFSee results (6)

More studies

1 study on this page

PubMed tag: none · 2017

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes.

Liu et al. 2017International journal of endocrinologycited by 7

PMID 29358950PMC5735665DOI 10.1155/2017/9401606PUB-29358950

CC BY
Download PDF

Eligibility

Who could join, as posted.

Sex
All
Age
from 20 Years up to 65 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * age 20 - \<65 years, * body mass index (BMI) ≥ 24 kg/m2, * HbA1c ≥ 7% (53mmol/mol). * diabetes antibodies (-) * diagnosed with T2D within the previous 3 months Exclusion Criteria: * anti-diabetic drugs or diet therapy before participation * pancreatitis * coronary artery disease * liver function impairment * renal function impairment * intestinal surgery * chronic hypoxic diseases (emphysema and cor pulmonale) * infectious disease * hematological disease * systemic inflammatory disease * cancer * pregnant, possibly pregnant * ingesting agents known to influence glucose or lipid metabolism

PepBank is a research reference. Talk to a doctor before you use any peptide.